465 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This comprehensive network meta-analysis provides crucial evidence for the comparative effectiveness of GLP-1 receptor and dual agonists in managing obesity. The findings strongly suggest that tirzepatide offers the m…
These findings represent a significant breakthrough, suggesting that Tirzepatide, a drug already approved for metabolic disorders, could be a novel and effective therapeutic strategy for cocaine use disorder. The abil…
This dual agonism approach offers a novel and potentially superior therapeutic strategy for advanced Type 2 Diabetes, addressing both the critical aspects of glycemic control and gut health, which are often severely c…
This review highlights a critical gap in our understanding of optimal T2DM management during pregnancy, particularly concerning newer, highly effective antidiabetic agents. The limited evidence for novel therapies mea…
This meta-analysis provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, could be a valuable adjunct therapy for Type 1 Diabetes patients, offering significant improvements in glycemic …
This comprehensive review underscores the transformative potential of incretin polyagonists to redefine obesity treatment paradigms. By offering a non-surgical option with efficacy approaching that of bariatric surger…
This study provides crucial evidence that Tirzepatide offers a powerful and effective therapeutic option for patients who require weight management but are also on medications known to induce weight gain. This signifi…
This study highlights that not all GLP-1 RAs are interchangeable regarding their safety profiles, providing crucial insights for personalized medicine. Clinicians can use this real-world evidence to make more informed…
This review highlights the significant challenge of maintaining weight loss and cardiometabolic improvements after discontinuing GLP-1 RA therapy, emphasizing that obesity is a chronic disease requiring long-term mana…
This study provides compelling real-world evidence suggesting tirzepatide offers superior cardiovascular protection compared to semaglutide in non-diabetic individuals with obesity. These findings are crucial for guid…
This comprehensive analysis provides crucial real-world insights into the safety profile of tirzepatide, confirming and quantifying the prevalence of its associated gastrointestinal adverse events. The identification …
This updated prevalence data highlights the growing acceptance and utilization of effective anti-obesity medications within a critical military population. Understanding these trends is vital for resource allocation, …
This comprehensive review provides crucial insights into the safety profile of tirzepatide for patients who stand to benefit most from its metabolic effects but also carry significant cardiovascular risk. The finding …
This review significantly advances our understanding of resistant and refractory obesity, moving beyond simplistic views of treatment failure. By categorizing the complex factors involved, it provides a crucial roadma…
This comprehensive review significantly advances our understanding of the multifaceted actions of GLP-1 Receptor Agonists, extending beyond their well-known direct metabolic effects. The identified interplay between G…
These findings are crucial for informing prescribing practices and patient monitoring for individuals on GLP-1 RAs, especially those with pre-existing diabetic eye disease. Given the widespread and increasing use of t…
This study provides crucial real-world insights into the safety profile of GLP-1 RAs, emphasizing the importance of monitoring for psychiatric adverse events beyond controlled clinical trial settings. The identificati…
This comprehensive, exposure-adjusted analysis provides robust evidence supporting the superiority of GLP-1 and GLP-1/GIP receptor agonists for managing obesity and type 2 diabetes. The findings reinforce their positi…
This study provides compelling real-world evidence that Tirzepatide effectively promotes significant additional weight loss even in patients who have already achieved initial weight reduction. This reinforces its util…
This study provides compelling evidence that tirzepatide offers superior cardiorenal protection compared to dulaglutide, a well-established GLP-1 RA, in patients with type 2 diabetes and cardiovascular disease. This s…
This meta-analysis provides crucial evidence supporting the potential utility of tirzepatide as a safe and effective treatment option for obesity and type 2 diabetes in organ transplant recipients. The demonstration o…
This case highlights a potentially rare but serious adverse effect of Tirzepatide, warranting increased awareness among clinicians. Recognizing drug-induced ITP is crucial for timely discontinuation of the offending a…
This study provides compelling evidence supporting the clinical benefit of switching patients with inadequately controlled Type 2 Diabetes from dulaglutide to tirzepatide. The consistent efficacy observed across diver…
This review underscores a crucial paradigm shift: the focus in obesity management is moving beyond simple weight loss to optimizing body composition for improved health outcomes. The findings highlight the significant…
This study provides compelling evidence that GLP-1 RAs, beyond their metabolic benefits, may offer a novel therapeutic approach for depressive symptoms and psychological well-being. The findings suggest a potential fo…
This real-world evidence suggests that GLP-1 and dual agonists may offer a critical additional benefit by preventing the onset of sleep apnea, a condition with significant long-term health consequences. This could tra…
This meta-analysis provides crucial insights into the comparative efficacy of three leading investigational therapies for MASLD, offering valuable guidance for clinical development and future treatment strategies. The…
This comprehensive review highlights the significant potential of incretin-mimetic drugs as a strategy for cancer prevention, especially in populations at high risk due to obesity and metabolic disorders. The findings…
These findings underscore the critical importance of recognizing and addressing racial disparities in treatment efficacy for obesity management. Understanding these differences in GLP-1RA response is crucial for devel…
This review underscores Tirzepatide's potential as a multifaceted therapeutic agent for a range of metabolic disorders, not just diabetes and obesity. Its broad impact on hepatic, cardiovascular, and renal health sugg…
This case report highlights the potential for Tirzepatide to address alcohol use disorder in patients with significant metabolic comorbidities. Given the high prevalence of type 2 diabetes and obesity in individuals w…
This comprehensive review is critical for guiding clinicians and policymakers in India to implement evidence-based and effective obesity management strategies. By synthesizing the latest data and expert consensus from…
The findings underscore the critical role of multi-targeted approaches in effectively treating the complex pathology of MASLD. This comprehensive overview provides a roadmap for future drug development, emphasizing th…
This review underscores the rapid and profound evolution of obesity pharmacotherapy, offering unprecedented hope for patients struggling with chronic weight management. The development of highly effective drugs like G…
The development of oral GLP-1 RAs represents a significant leap forward, offering a more convenient and patient-friendly option that can greatly improve adherence to treatment for Type 2 Diabetes. Furthermore, the adv…
This review underscores the transformative potential of GIP receptor-based therapies as a powerful new class of drugs for obesity management. The impressive weight loss and metabolic improvements observed suggest thes…
This research highlights the potent renoprotective capabilities of multi-agonist incretin therapies, particularly Retatrutide, in managing Diabetic Kidney Disease. The superior efficacy of Retatrutide, which targets G…
This comprehensive comparison provides crucial evidence for clinicians and patients, guiding treatment decisions for obesity and overweight. The identification of most effective agents can lead to more personalized an…
This review underscores a transformative era in obesity management, moving beyond modest weight loss to therapies offering substantial and sustained reductions. The comprehensive overview provided by the authors is cr…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This study provides crucial, evidence-based insights into the comparative efficacy and safety of available GLP-1 RAs, offering a clear hierarchy of their weight reduction capabilities. The findings highlight that newe…
This review underscores the transformative potential of GLP-1RAs in addressing the global obesity epidemic and its related health burdens. The significant and sustained weight loss observed with these agents, coupled …
This review underscores the transformative potential of incretin-based therapies in combating the complex challenges of obesity and its comorbidities. By providing a comprehensive overview of their efficacy and safety…
This comprehensive NMA provides crucial evidence supporting the superior efficacy of multi-receptor agonists like retatrutide and tirzepatide over single GLP-1 RAs for significant weight loss in adults with overweight…